ArticleFrontiers in pharmacology2025
Impact of postoperative flurbiprofen axetil on renal function in spontaneously hypertensive rats.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Renal safety of postoperative short-term use of flurbiprofen axetil in well-controlled hypertensive patients: a prospective multicenter cohort study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Flurbiprofen axetil (FA) is a nonsteroidal anti-inflammatory drug frequently used in postoperative analgesia. However, limited data exist regarding its impact on renal profiles. Here we determine the potential impact of postoperative FA on renal function in spontaneously hypertensive (SH) rats. Methods: A plantar incision model was established to mimic post-surgical pain in SH rats. Animals were randomly assigned to groups called vehicle (fat emulsion, 0.5 mL/d), low-dose FA (H12.5, 12.5 mg/kg/d), medium-dose FA (H25, 25 mg/kg/d) or high-dose FA (H50, 50 mg/kg/d). Analogously, 40 male Wistar Kyoto (WKY) rats were included as controls in groups called vehicle, C12.5, C25, and C50. The vehicle and different doses of FA were administered from the day of surgery through postoperative day 2 (POD2). Paw withdrawal thresholds (PWTs) were measured before and after incision. Urinary N-acetyl-β-D-glucosaminidase (NAG), serum creatinine (SCr), and Cystatin C (Cys C) were measured. Animals were sacrificed for renal pathology analysis on POD7. Results: PWTs exhibited a dose-dependent increase after postoperative administration of FA on POD1 and POD2, but with a ceiling effect at the medium dose in both SH and WKY rats. Compared with the vehicle group, the levels of SCr in the C50, H25, and H50 groups were significantly increased on POD2 and POD7 (all P < 0.01). The concentration of Cys C in C12.5, C25, and C50 groups, as well as H12.5, H25, and H50 groups on POD2, were increased in a dose-dependent manner (all P < 0.05), similar trend was detected in H25, and H50 groups on POD7. Urine NAG levels in the H12.5, H25 and H50 groups on POD2, as well as H25 and H50 groups on POD7 were elevated in comparison with the vehicle groups (all P < 0.05). Partial glomerular and tubular damage was found in the H25 group. Extensive renal impairments were observed in the C50 and H50 groups. Conclusion: Medium-dose FA effectively alleviates postoperative pain and achieves a ceiling effect in SH rats. FA decreases glomerular and tubular function to a certain extent in both normo- and hypertensive rats. Renal impairment is detectable earlier after surgery in hypertensive rats, even at the lowest FA dose applied here.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.